Accéder au contenu
MilliporeSigma
Toutes les photos(2)

Principaux documents

HCYTMAG-60K-PX29

Millipore

MILLIPLEX® Human Cytokine/Chemokine Magnetic Bead Panel - Premixed 29 Plex - Immunology Multiplex Assay

Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.

Synonyme(s) :

Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12161503
eCl@ss :
32161000

Espèces réactives

human

Fabricant/nom de marque

Milliplex®

assay range

accuracy: 87-107%
standard curve range: 3.2-10,000 pg/mL

Technique(s)

multiplexing: suitable

Compatibilité

configured for Premixed

Méthode de détection

fluorometric (Luminex xMAP)

Conditions d'expédition

wet ice

Description générale

“Cytokine” is a general term used for a diverse group of soluble proteins and peptides which act as regulators under both normal and pathological conditions to modulate the functional activities of individual cells and tissues. These proteins also mediate direct interactions between cells and regulate processes taking place in the extracellular environment. Cytokines differ from hormones in that they act on a wider spectrum of target cells. Also, unlike hormones, they are not produced by specialized cells which are organized in specialized glands. The cytokine group of proteins includes lymphokines, interferons, colony stimulating factors and chemokines. Cytokine and chemokine research plays a significant role in achieving a deeper understanding of the immune system and its multi-faceted response to most antigens, as well as disease states such as inflammatory disease, allergic reactions, irritable bowel disease (IBD), sepsis, and cancer.

The MILLIPLEX® Human Cytokine / Chemokine Panel 1 enables you to focus on the therapeutic potential of cytokines as well as the modulation of cytokine expression.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

Spécificité

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: EGF, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, TNF-β, VEGF, Eotaxin/CCL11
  • Recommended Sample type: Serum, plasma, or tissue/cell lysate and culture supernatant samples
  • Recommended Sample dilution: Neat plasma or serum. Tissue culture supernatant may require a dilution with an appropriate control medium prior to assay.
  • Assay Run Time: Overnight or two-hour primary incubation. For best results, an overnight incubation is recommended
  • Research Category: Inflammation & Immunology
  • Research Subcategory: Obesity, Metabolic Disorders, Inflammation & Autoimmune Mechanisms

Conditionnement

96 well plate

Stockage et stabilité

Recommended storage for kit components is 2 - 8°C.

Autres remarques

Note: RANTES, PDGF-AA and PDGF-AB/AA cannot be plexed with other analytes for serum/plasma.
Sensitivity: Refer to kit protocol for sensitivities for individual cytokines/chemokines.

Informations légales

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Organes cibles

Respiratory Tract

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Rodolfo Soria-Castro et al.
Journal of leukocyte biology (2021-06-01)
The immune response plays a critical role in the pathophysiology of SARS-CoV-2 infection ranging from protection to tissue damage and all occur in the development of acute respiratory distress syndrome (ARDS). ARDS patients display elevated levels of inflammatory cytokines and
Yasuhiro Oki et al.
British journal of haematology, 171(4), 463-470 (2015-07-28)
We conducted a phase II study of the AKT inhibitor, MK2206 in patients with relapsed or refractory lymphoma of any histology excluding Burkitt lymphoma or lymphoblastic lymphoma. MK-2206 was administered orally at 200 mg once weekly in 28-d cycles up to
Yasuhiro Oki et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19(24), 6882-6890 (2013-10-08)
To evaluate the safety and efficacy of panobinostat plus everolimus in patients with relapsed Hodgkin and non-Hodgkin lymphoma. The concept was supported by the single-agent clinical activity of histone deacetylase inhibitors and mTOR inhibitors, and on the in vitro mechanism-based
Carley Tasker et al.
JCI insight, 1(20), e88255-e88255 (2016-12-13)
IFN-ε is a unique type I IFN that is not induced by pattern recognition response elements. IFN-ε is constitutively expressed in mucosal tissues, including the female genital mucosa. Although the direct antiviral activity of IFN-ε was thought to be weak
Ellen Kraig et al.
Experimental gerontology, 105, 53-69 (2018-02-07)
Inhibition of the mechanistic target of rapamycin (mTOR) pathway by rapamycin (RAPA), an FDA-approved immunosuppressive drug used as a clinical therapy to prevent solid organ allograft rejection, enhances longevity in mice. Importantly, RAPA was efficacious even when initiated in relatively

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique